Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dusa Patent Suit Challenges Compounding Of Levulan

This article was originally published in The Pink Sheet Daily

Executive Summary

New England Compounding Center’s compounding of aminolevulinic acid HCl goes beyond the activities permitted under the FD&C Act, Dusa maintains. The company has also told FDA about its concerns.

You may also be interested in...



FDA’s Compounding Oversight: What Price Safety?

As meningitis outbreak widens, FDA and members of Congress are calling for clarification of what jurisdiction the agency has over pharmacies, but agency officials are stopping short of asking for clear new authorities.

Dusa Settles Compounding Suit

Dusa has reached a settlement with the New England Compounding Center in its patent infringement lawsuit relating to compounded Levulan (aminolevulinic acid), Dusa said April 10

Dusa Settles Compounding Suit

Dusa has reached a settlement with the New England Compounding Center in its patent infringement lawsuit relating to compounded Levulan (aminolevulinic acid), Dusa said April 10

Related Content

Topics

UsernamePublicRestriction

Register

PS058475

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel